Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoViricides, Inc. Appoints Id3A, LLC as Architect for its previously announced cGMP Production and Laboratory Facility

Abstract:
NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has retained Id3A, LLC ("Id3A"), as the architect for its laboratory and cGMP pilot production facility project. As previously announced, this facility will be built by renovating an existing 18,000 sq. ft. light manufacturing plant on a 4.2 acre lot in Shelton, CT. Ms. Kathyann Cowles, AIA, will serve as the Principal Architect for the project. Id3A recently began working with the Company for the architecture portion and now the Company has formally engaged Id3A as the architects for this project. Id3A will be responsible for the overall facility architecture, including integration of a separately constructed Clean Room Suite for cGMP production. Ms Cowles will join Mr. Andrew Hahn and Mr. Phil Mader of MPH Engineering, LLC (MPH) to complete our architecture, design and construction management team. As previously announced, Mr. Hahn continues to provide overall stewardship of the project, while Mr. Mader is responsible for detailed project management, and his firm, MPH, is providing engineering services.

NanoViricides, Inc. Appoints Id3A, LLC as Architect for its previously announced cGMP Production and Laboratory Facility

West Haven, CT | Posted on January 2nd, 2013

Ms. Cowles, co-founder of Id3A, has over thirty years of experience as a licensed Architect and Senior Project Manager for diverse and complex design and construction projects in the academic, science, technology, corporate and research sectors. Id3A, a women-owned business, was co-founded by Ms. Cowles and Ms. Demko, and it acquired the Connecticut practice of Perkins+Will in 2001.

Prior to founding Id3A, Ms. Cowles has worked on a variety of projects in the Pharma, Medical, Academic, and Science sectors. These include Chemistry and Biology (BL4) Lab Renovations, an MRI Suite, and CADD and SATT Lab projects at the Bristol-Myers-Squibb Company in Wallingford, CT. Other projects include Northeastern University's New Biomedical Research Facility, Yale University's Osborne Research Lab; as well as Operating Rooms, Wound Care Units, Histology, and other Labs at renowned hospitals including Greenwich Hospital, CT, Englewood Hospital, NJ, and Windham Hospital, CT. She has won several prestigious awards during her distinguished career.

"Ms. Cowles has a unique ability to work with clients in meeting complex and detailed requirements," said Anil R. Diwan, PhD, President of the Company, adding, "This is critically important for our challenging project that specifies not only state-of-the-art facility requirements, but also cost sensitivity, space efficiency, and a high degree of energy efficiency."

The Company has previously reported about the Shelton light industrial building that will house the cGMP pilot production plant, research laboratories, and offices. The cGMP pilot plant is being designed for the production of sufficient quantities of the drug needed for human clinical trials for each of the various nanoviricides® drug candidates as they advance into the clinical pipeline.

The light industrial building at 1 Controls Drive, Shelton CT was purchased by Inno-Haven, LLC. Inno-Haven is a private company that was founded by Dr. Anil R. Diwan, the Company's CEO, and financed by himself and certain of his friends and associates, with the specific purpose of enabling clinical cGMP manufacturing capabilities for NanoViricides, Inc. drug substances. Acquisition of this 18,000 sqft building on 4.2 acres of land was previously announced by NanoViricides, Inc. in September, 2011. Renovation of the building is to be performed as per the requirements of NanoViricides, Inc. for the production of the nanoviricides drug candidates for clinical trials under cGMP processes. The drug substance produced in this facility will then be delivered to a third party for final processing and labeling, as required, for human clinical trials when ready. NanoViricides, Inc. expects to lease this facility. No lease has been signed yet and no terms of lease have been finalized as of now.

####

About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the Company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

For more information, please click here

Contacts:


NanoViricides, Inc.
Amanda Schuon
310-550-7200

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New chip promising for tumor-targeting research September 22nd, 2014

Twisted graphene chills out: When two sheets of graphene are stacked in a special way, it is possible to cool down the graphene with a laser instead of heating it up, University of Manchester researchers have shown September 22nd, 2014

New star-shaped molecule breakthrough: Scientists at The University of Manchester have generated a new star-shaped molecule made up of interlocking rings, which is the most complex of its kind ever created September 22nd, 2014

Iranian Researchers Synthesize Stable Ceramic Nanopowders at Room Temperature September 20th, 2014

Openings/New facilities/Groundbreaking/Expansion

FEI Opens New Technology Center in Czech Republic: FEI expands its presence in Brno with the opening of a new, larger facility September 18th, 2014

Nanophase Opens New Polishing Applications Support Laboratory September 9th, 2014

RMIT delivers $30m boost to micro and nano-tech August 26th, 2014

SEMATECH and Newly Merged SUNY CNSE/SUNYIT Launch New Patterning Center to Further Advance Materials Development: Center to Provide Access to Critical Tools that Support Semiconductor Technology Node Development August 7th, 2014

Nanomedicine

New chip promising for tumor-targeting research September 22nd, 2014

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

The Pocket Project will develop a low-cost and accurate point-of-care test to diagnose Tuberculosis: ICN2 holds a follow-up meeting of the Project on September 18th - 19th September 18th, 2014

Recruiting bacteria to be technology innovation partners: September 17th, 2014

Announcements

New chip promising for tumor-targeting research September 22nd, 2014

Twisted graphene chills out: When two sheets of graphene are stacked in a special way, it is possible to cool down the graphene with a laser instead of heating it up, University of Manchester researchers have shown September 22nd, 2014

New star-shaped molecule breakthrough: Scientists at The University of Manchester have generated a new star-shaped molecule made up of interlocking rings, which is the most complex of its kind ever created September 22nd, 2014

Synthesis of Nanostructures with Controlled Shape, Size in Iran September 22nd, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE